Clobazam is currently available as oral tablets and suspension under the trade name Onfi (Lundbeck).
This marks the first approved drug that contains an active ingredient derived from marijuana as well as the first treatment approved for patients with Dravet syndrome.
Cannabidiol plus conventional antiepileptics reduces drop seizure frequency in the Lennox-Gastaut syndromeMay 24, 2018
Amongst adults and children with the Lennox-Gastaut syndrome, addition of cannabidiol to a conventional antiepileptic regimen reduced drop seizure frequency compared to placebo treated patients.
Add-on cannabidiol is associated with reduced monthy drop seizure frequency in patients with Lennox-Gastaut sydrome associated drop seizures.
The FDA has accepted for filing with Priority Review the NDA for cannabidiol as seizure treatment.
Clobazam is currently FDA-approved for the treatment of seizures associated with Lennox-Gastaut syndrome in children 2 years and older.
Cannabidiol Effective for Reducing Drop Seizures in Lennox-Gastaut Syndrome Regardless of Clobazam UseDecember 03, 2017
The study was a post-hoc analysis of responders who were on or off concomitant clobazam.
Add-on Cannabidiol Generally Safe for Treatment-Resistant Epilepsy, Dravet, Lennox-Gastaut SyndromesDecember 02, 2017
Adverse reactions in the CBD group included decreased appetite, diarrhea, fatigue, lethargy, nasopharyngitis, pneumonia, pyrexia, rash, and somnolence.
Anup Patel, MD, of Nationwide Children's Hospital and The Ohio State University School of Medicine, discusses findings from a dose-ranging study of cannabidiol for the treatment of drop seizures in Lennox-Gastaut syndrome. Scroll to below the video for a full text transcript of Dr Patel's interview.
Results from 2 phase 3 clinical trials demonstrated efficacy of adjunctive cannabidiol for the treatment of drop seizures in Lennox-Gastaut syndrome.
Elizabeth Thiele, MD, PhD discusses results from her research on cannabidiol in Lennox-Gastaut syndrome.
Justin Gover, CEO of GW Pharmaceuticals, the parent company of Greenwich Biosciences, discusses the status of the company's cannabidiol product Epidiolex on the heels of positive results from several placebo-controlled trials in epileptic syndromes.
Patients taking cannabidiol experienced a significant reduction in drop seizures compared with placebo.
Dr Elizabeth Thiele discusses the latest on cannabidiol research for the treatment of refractory epilepsy.
The study translated the primary end point into a clinical benefit for patients.
The drug has already been given Orphan Drug and Fast Track Designation for the treatment of Dravey syndrome.
A large, multi-center study found cannabidiol effective for the reduction of seizures
Mutations were identified in 7 genes, including one for the first time.
Implementing a ketogenic diet in patients with drug-resistant epilepsy could produce significant reductions in seizure frequency.
New data supports the use of resective surgery in patients with Lennox-Gastaut syndrome.
Patients and parents perceive cannabidiol as effective in treating seizures, but the evidence is largely anecdotal.
Clobazam was safe and effective in reducing atonic seizures among patients with Lennox-Gestaut syndrome who participated in the CONTAIN trial.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL